Patents by Inventor Sanjeev Gangwar

Sanjeev Gangwar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240165249
    Abstract: Methods of making compounds represented by formula (I) can be used to make antibody-drug conjugates. The conjugates so made are stable in both human and mouse serum, enabling the performance of pre-clinical studies using a mouse model.
    Type: Application
    Filed: January 16, 2024
    Publication date: May 23, 2024
    Inventors: Yam B. POUDEL, Sanjeev GANGWAR
  • Patent number: 11911483
    Abstract: Compounds represented by formula (I) can be used to make antibody-drug conjugates. The conjugates so made are stable in both human and mouse serum, enabling the performance of pre-clinical studies using a mouse model.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: February 27, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yam B. Poudel, Sanjeev Gangwar
  • Publication number: 20230348468
    Abstract: Compounds according to formula I or II are useful as agonists of Toll-like receptor 7 (TLR7). (I) (II) Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Application
    Filed: January 26, 2021
    Publication date: November 2, 2023
    Inventors: Matthew COX, Naidu S. CHOWDARI, Ashvinikumar V. GAVAI, Sanjeev GANGWAR, Christine M. TARBY, Yam B. POUDEL, Murugaiah ANDAPPAN MURUGAIAH SUBBAIAH
  • Publication number: 20230159552
    Abstract: Compounds according to formula (I), where R is as defined herein, have anti-cancer properties.
    Type: Application
    Filed: April 8, 2021
    Publication date: May 25, 2023
    Inventors: Dale L. BOGER, Naidu S. CHOWDARI, Sanjeev GANGWAR
  • Publication number: 20230144824
    Abstract: Compounds according to formula I or II are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Application
    Filed: January 26, 2021
    Publication date: May 11, 2023
    Inventors: Liqi HE, Ashvinikumar V. GAVAI, Sanjeev GANGWAR, Qiang CONG, Yam B. POUDEL, Prasanna SIVAPRAKASAM, Christine M. TARBY, Patrice GILL, Andrew F. DONNELL, Murugaiah ANDAPPAN MURUGAIAH SUBBAIAH
  • Publication number: 20230140047
    Abstract: Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Application
    Filed: December 14, 2022
    Publication date: May 4, 2023
    Inventors: YAM B. POUDEL, Sanjeev GANGWAR, Liqi HE, Prasanna SIVAPRAKASAM, Matthias BROEKEMA, Matthew COX, Christine M. TARBY, Qian ZHANG, Naidu S. CHOWDARI
  • Publication number: 20230140430
    Abstract: Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Application
    Filed: January 26, 2021
    Publication date: May 4, 2023
    Inventors: Matthew COX, Liqi HE, Sanjeev GANGWAR, Ashvinikumar V. GAVAI, Matthias BROEKEMA, Qiang CONG, Daniel O'MALLEY, Yam B. POUDEL, Christine M. TARBY
  • Publication number: 20230127326
    Abstract: Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Application
    Filed: January 26, 2021
    Publication date: April 27, 2023
    Inventors: Christine M. TARBY, Qiang CONG, Ashvinikumar V. GAVAI, Sanjeev GANGWAR, Matthias BROEKEMA, Patrice GILL, Prasanna SIVAPRAKASAM, Walter L. JOHNSON, Murugaiah Andappan Murugaiah SUBBAIAH, Yam B. POUDEL
  • Publication number: 20230131192
    Abstract: Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). (I) Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Application
    Filed: January 26, 2021
    Publication date: April 27, 2023
    Inventors: Christine M. TARBY, Matthias BROEKEMA, Ashvinikumar V. GAVAI, Sanjeev GANGWAR, Naidu S. CHOWDARI, Walter L JOHNSON, Murugaiah ANDAPPAN MURUGAIAH SUBBAIAH
  • Publication number: 20230130516
    Abstract: Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Application
    Filed: January 26, 2021
    Publication date: April 27, 2023
    Inventors: Qian ZHANG, Sanjeev GANGWAR, Ashvinikumar V. GAVAI, Qiang CONG, Yam B. POUDEL, Liqi HE, Prasanna SIVAPRAKASAM, Christine M. TARBY
  • Publication number: 20230118688
    Abstract: Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Application
    Filed: January 26, 2021
    Publication date: April 20, 2023
    Inventors: Heng CHENG, Christine M. TARBY, Sanjeev GANGWAR, Ashvinikumar V. GAVAI, Walter L. JOHNSON, Yam B. POUDEL, Prasanna SIVAPRAKASAM, Patrice GILL, Andrew F. DONNELL, Murugaiah Andappan Murugaiah SUBBAIAH
  • Publication number: 20230122249
    Abstract: Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). (I) Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Application
    Filed: January 26, 2021
    Publication date: April 20, 2023
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Yam B. POUDEL, Matthew COX, Liqi HE, Daniel O'MALLEY, Ashvinikumar V. GAVAI, Sanjeev GANGWAR, Matthias BROEKEMA, Prasanna SIVAPRAKASAM, Christine M. TARBY, Murugaiah ANDAPPAN MURUGAIAH SUBBAIAH,Murugaiah
  • Publication number: 20230041738
    Abstract: Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). (I) Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Application
    Filed: January 26, 2021
    Publication date: February 9, 2023
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Yam B. POUDEL, Matthew COX, Liqi HE, Ashvinikumar V. GAVAI, Sanjeev GANGWAR, Mathias BROEKEMA, Christine M. TARBY, Murugaiah ANDAPPAN MURUGAIAH SUBBAIAH
  • Patent number: 11554120
    Abstract: Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: January 17, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yam B. Poudel, Sanjeev Gangwar, Liqi He, Prasanna Sivaprakasam, Matthias Broekema, Matthew Cox, Christine M. Tarby, Qian Zhang, Naidu S. Chowdari
  • Patent number: 11485741
    Abstract: Compounds having a structure according to formula are modulators of TLR7 activity and can be used to treat conditions amenable to treatment by the modulation of TLR7 activity.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: November 1, 2022
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Ashok V. Purandare, Honghe Wan, Liqi He, Sanjeev Gangwar, Shoshana L. Posy, Yam B. Poudel, Prasanna Sivaprakasam, Naidu S. Chowdari
  • Patent number: 11400094
    Abstract: Compounds according to formula II are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Grant
    Filed: August 1, 2019
    Date of Patent: August 2, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yam B. Poudel, Sanjeev Gangwar, Liqi He, Prasanna Sivaprakasam
  • Patent number: 11020490
    Abstract: In antibody-drug conjugates having tubulysin analog as the warhead, according to formula (III) the acetate group in the Tuv subunit (dotted box) demonstrates improved stability against hydrolytic cleavage.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: June 1, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ian S. Young, Sha Lou, Sanjeev Gangwar
  • Publication number: 20210113706
    Abstract: Compounds represented by formula (I) can be used to make antibody-drug conjugates. The conjugates so made are stable in both human and mouse serum, enabling the performance of pre-clinical studies using a mouse model.
    Type: Application
    Filed: December 18, 2020
    Publication date: April 22, 2021
    Inventors: Yam B. POUDEL, Sanjeev GANGWAR
  • Patent number: 10981914
    Abstract: Compounds having a structure according to formula (I), (II), or (III) where R1, R2, R3, R5 X1, X2, and X3 are as defined herein, are agonists for the Toll-like receptor 7 (TLR7) and can be used as adjuvants for stimulating the immune system. Some such compounds can be used in conjugates for targeted delivery to the organ or tissue of intended action.
    Type: Grant
    Filed: September 23, 2019
    Date of Patent: April 20, 2021
    Assignee: Bristol-Myers Squibb Companay
    Inventors: Ian S. Young, Sanjeev Gangwar, Shoshana L. Posy, Yam B. Poudel, Prasanna Sivaprakasam
  • Patent number: 10941145
    Abstract: Compounds having a structure according to formula (I) where R1, R2, and R3 are as defined herein, are agonists for the Toll-like receptor 7 (TLR7) and can be used as adjuvants for stimulating the immune system. Some such compounds can be used in conjugates for targeted delivery to the organ or tissue of intended action.
    Type: Grant
    Filed: June 2, 2020
    Date of Patent: March 9, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yam B. Poudel, Sanjeev Gangwar, Prasanna Sivaprakasam, Shoshana L. Posy